NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease

Keywords

Disease, Alzheimer's disease, Psychology, Neuroscience, Medicine

References

• Desktop medicine.歩美 坂田, 浩 原田 — 2010
• Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.Bassam A Chokr — 2012
• Injury markers predict time to dementia in subjects with MCI and amyloid pathology真実智 高森, 重剛 伊藤 — 2012
• Age-specific population frequencies of amyloidosis and neurodegeneration among cognitively normal people age 50-89 years: a cross-sectional study一喜 武井 — 2014
• Early and late change on the preclinical Alzheimer’s cognitive composite in clinically normal older individuals with elevated β-amyloidDonna L. Washington, Paul G Shekelle, Carl D. Stevens — 2017
• Neuropathology of Cognitively Normal ElderlyDavid S. Knopman, Joseph E. Parisi, Alessandro Salviati — 2003
• Neuropsychiatric symptoms as early manifestations of emergent dementia: Provisional diagnostic criteria for mild behavioral impairmentZahinoor Ismail, Eric E. Smith, Yonas E. Geda — 2015
• Suspected non-AD pathology in Mild Cognitive ImpairmentLaura E.M. Wisse, Nirali Butala, Sandhitsu R. Das — 2015
• Cognitive and Brain Profiles Associated with Current Neuroimaging Biomarkers of Preclinical Alzheimer's DiseaseFlorent L. Besson, Renaud La Joie, Loïc Doeuvre — 2015
• The Neuropathology of Older Persons with and Without Dementia from Community versus Clinic CohortsJulie A. Schneider, Neelum T. Aggarwal, Lisa L. Barnes — 2009
• Criteria for Mild Cognitive Impairment Due to Alzheimer’s Disease in the CommunityRonald C. Petersen, Paul Aisen, Bradley F. Boeve — 2013
• The Cortical Signature of Alzheimer's Disease: Regionally Specific Cortical Thinning Relates to Symptom Severity in Very Mild to Mild AD Dementia and is Detectable in Asymptomatic Amyloid-Positive IndividualsBradford C. Dickerson, Akram Bakkour, David H. Salat — 2008
• Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer DiseaseMaartje I. Kester, Charlotte E. Teunissen, Daniel L. Crimmins — 2015
• The Global Deterioration Scale for assessment of primary degenerative dementia.‌Barry Reisberg, Steven H. Ferris, Mony J. de Leon — 1982
• Prevalence of Amyloid PET Positivity in Dementia SyndromesRik Ossenkoppele, Willemijn J. Jansen, Gil D. Rabinovici — 2015
• TNM Classification of Malignant Tumours, 7th EditionCh. Wittekind, Mary Gospodarowicz, Leslie H. Sobin — 2009
• [18F]flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: Specific detection of advanced phases of amyloid‐β pathologyDietmar Rudolf Thal, Thomas G. Beach, Michelle Zanette — 2015
• Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease ProgressionHenrik Zetterberg, Tobias Skillbäck, Niklas Mattsson — 2016
• Brain Injury Biomarkers Are Not Dependent on β-amyloid in Normal ElderlyDavid S. Knopman, Clifford R. Jack, Heather J. Wiste — 2013
• Testing the Right Target and the Right Drug at the Right StageReisa A. Sperling, Clifford R. Jack, Paul Aisen — 2011

Cited by

• Subjective Cognitive Decline and APOE ɛ4: A Systematic ReviewJordan I. Ali, Colette M. Smart, Jodie R. Gawryluk — 2018
• AMYPAD Diagnostic and Patient Management Study: Rationale and designFrancisco Álvarez, Emilio Cerdá Tena — 2018
• Is Alzheimer’s Disease Risk Modifiable?健吾 永岡, 徹也 赤木, 誠之 鰺坂 — 2019
• The effects of 7‐week cognitive training in patients with vascular cognitive impairment, no dementia (the Cog‐VACCINE study): A randomized controlled trialChangjiu Xian, David D. Nolte, L. J. Pyrak‐Nolte — 2019
• Clinical Effects of Frontal Behavioral Impairment: Cortical Thickness and Cognitive Decline in Individuals with Subjective Cognitive Decline and Amnestic Mild Cognitive ImpairmentSeung Joo Kim, Na‐Yeon Jung, Young Ju Kim — 2019
• Amyloid PET and cognitive decline in cognitively normal individuals: the SCIENCe project.Alfredo Mela, Luca Staricco — 2019
• Metabolic network alterations as a supportive biomarker in dementia with Lewy bodies with preserved dopamine transmissionMichael J. Keller, Suzanne Hughes — 2023
• Neuropsychological subtypes of incident mild cognitive impairment in the Mayo Clinic Study of AgingMary M. Machulda, Emily S. Lundt, Sabrina M. Albertson — 2017
• Altered Bile Acid Profile in Mild Cognitive Impairment and Alzheimer’s Disease: Relationship to Neuroimaging and CSF BiomarkersKwangsik Nho, Alexandra Kueider‐Paisley, Siamak MahmoudianDehkordi — 2018
• Will biomarker-based diagnosis of Alzheimer’s disease maximize scientific progress? Evaluating proposed diagnostic criteriaM. Maria Glymour, Adam M. Brickman, Mika Kivimäki — 2018
• Left lateralized cerebral glucose metabolism declines in amyloid-β positive persons with mild cognitive impairmentChristopher M. Weise, Kewei Chen, Yinghua Chen — 2018
• CSF biomarkers of neuroinflammation and cerebrovascular dysfunction in early Alzheimer diseaseShorena Janelidze, Niklas Mattsson, Erik Stomrud — 2018
• Plasma Aβ42 as a Biomarker of Prodromal Alzheimer’s Disease Progression in Patients with Amnestic Mild Cognitive Impairment: Evidence from the PharmaCog/E-ADNI StudyDiego Albani, Moira Marizzoni, Clarissa Ferrari — 2018
• In vivo mapping of brainstem nuclei functional connectivity disruption in Alzheimer's disease.Laura Serra, Marcello D’Amelio, Carlotta Di Domenico — 2018
• Neuropathologic Correlates of Psychiatric Symptoms in Alzheimer’s DiseaseAlexander J. Ehrenberg, Cláudia Kimie Suemoto, Elisa de Paula França Resende — 2018
• The intact postsynaptic protein neurogranin is reduced in brain tissue from patients with familial and sporadic Alzheimer’s diseaseHlin Kvartsberg, Tammaryn Lashley, Christina E. Murray — 2018
• Mild cognitive impairment in long-term brain tumor survivors following brain irradiationChristina K. Cramer, Neil McKee, L. D. Case — 2018
• Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging InitiativeDallas P. Veitch, Michael W. Weiner, Paul Aisen — 2018
• Association of Cerebrospinal Fluid Neurofilament Light Protein With Risk of Mild Cognitive Impairment Among Individuals Without Cognitive ImpairmentSilke Kern, Jeremy A. Syrjanen, Kaj Blennow — 2019
• Evidenzbasierte Pharmakotherapie der Alzheimer-DemenzKristina Gartzen, Richard Dodel — 2018

Related papers

• ИСПОЛЬЗОВAНИЕ ПОТЕНЦИAЛA СОЦИAЛЬНЫХ ПAРТНЕРОВ В ПОДГОТОВКЕ БУДУЩИХ ПЕДAГОГОВБ.Б. Атaбекова — 2024
• DETERMINING QUALITY REQUIREMENTS AT THE UNIVERSITIES TO IMPROVE THE QUALITY OF EDUCATIONNor Hanim Mustafa, Dinmukhamed Kelesbayev, Zh.D. Alibekova — 2018
• Genentech taps Affimed’s antibodiesRyan Cross — 2018
• KOMPLIKASI REGIONAL ANESTESI PADA PEDIATRIKDjayanti Sari — 2023
• Enxerto livre de arteria epigastrica inferior: avaliacao hemodinamica e angiografica pre e pos-operatoriaAbraham Dib, Luiz Bóro Puig, Décio Salvadori — 1988
• Cardiac retransplantation in children.Kirk R. Kanter, Robert Vincent, Alexandria M. Berg — 2004
• Avaliacao hemodinamica sequencial em transplante de coracaoAngela Fiorelli, Noedir Antônio Groppo Stolf, L F Moreira — 1987
• Thoracoscopic discectomy and fusion in the treatment of spinal deformitiesMehmet Akif Kaygusuz, Mustafa Şahin, İrfan Esenkaya — 1999